Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730726 | 0.85 | RAB9A (0.45) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730838 | 0.83 | RAB9A (0.42) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730721 | 0.81 | USP30 (0.49) | — | |
| SCHEMBL14730766 | 0.81 | RAB9A (0.47) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730768 | 0.81 | RAB9A (0.50) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730798 | 0.80 | RAB9A (0.44) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730799 | 0.80 | SMYD3 (0.55) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730847 | 0.80 | SMYD3 (0.55) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL14730796 | 0.80 | KDR (0.46) | TLR8TLR7PRMT1RAB9ASUV39H1 | |
| SCHEMBL14730722 | 0.80 | KDR (0.46) | TLR8TLR7PRMT1RAB9ASUV39H1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | TLR9 3787/4885TLR8 3173/4885TLR7 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.